Form 4: KKR Sells 6 Million Shares of BridgeBio Pharma (BBIO) in Block Trade

KKR Genetic Disorder L.P. sold 6 million shares of BridgeBio Pharma at $32.96 per share.

Summary

• KKR Genetic Disorder L.P. sold 6,000,000 shares of BridgeBio Pharma, Inc. (BBIO) common stock on March 5, 2025.
• The sale was executed at a price of $32.96 per share, totaling $197,760,000.
• The transaction was conducted as a block sale pursuant to Rule 144 of the Securities Act of 1933.
• Following the sale, KKR Genetic Disorder L.P. indirectly holds 19,260,971 shares of BridgeBio Pharma.
• Several KKR entities and individuals, including KKR Genetic Disorder GP LLC, KKR Group Partnership L.P., KKR Group Holdings Corp., KKR Group Co. Inc., KKR & Co. Inc., KKR Management LLP, Henry R. Kravis, and George R. Roberts, are associated with the reporting person.
• These entities and individuals disclaim beneficial ownership of the reported securities, except to the extent of their pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral. It's a standard transaction (share sale) by a major shareholder. The impact on the company depends on market perception and the company's fundamentals.

Negatives

• The sale of a large block of shares by a major shareholder like KKR could potentially exert downward pressure on the stock price of BridgeBio Pharma.

Risks

• The market may interpret the sale as a lack of confidence in BridgeBio Pharma's future prospects, potentially leading to a decline in investor sentiment.
• Further sales by KKR or other major shareholders could exacerbate downward pressure on the stock price.

Industry Context

Block trades by major shareholders are common in the biotech industry, often driven by portfolio rebalancing or profit-taking. The impact on the stock price depends on market perception and the company's fundamentals.

Comparison to Industry Standards

• Comparable block trades in the biotech industry have shown varying impacts on stock prices, ranging from minimal effect to short-term declines followed by recovery.
• The market's reaction will likely depend on BridgeBio Pharma's pipeline progress, upcoming clinical trial results, and overall market sentiment towards the biotech sector.
• Similar transactions involving companies like Amgen or Gilead Sciences have demonstrated that strong underlying fundamentals can mitigate negative impacts from large share sales.

Stakeholder Impact

• Shareholders may experience short-term price volatility.
• Employees may be concerned about the long-term implications of the sale.
• The company's reputation could be affected depending on how the market interprets the transaction.

Key Dates